Seeking Alpha

Eli Lilly (LLY) -5.1% after saying it will carry out another Phase III trial of its solanezumab...

Eli Lilly (LLY) -5.1% after saying it will carry out another Phase III trial of its solanezumab treatment in patients with mild symptoms of Alzheimer's disease, and will delay applying for approval in the U.S. and Europe following meetings with regulators. The postponement is unlikely to surprise SA author Brian Wilson, who pointed out that apparent patient improvement in two previous studies was "not statistically significant." (PR)
Comments (3)
  • chopchop0
    , contributor
    Comments (3796) | Send Message
    a good entry point?
    12 Dec 2012, 08:20 AM Reply Like
  • wk680
    , contributor
    Comments (3) | Send Message
    Don't do it. This stock has nowhere to go but down. This time next year loses their last cash cow (Cymbalta) and the pipeline is garbage at best.
    12 Dec 2012, 08:51 AM Reply Like
  • chopchop0
    , contributor
    Comments (3796) | Send Message
    yeah I was looking at the 10-year chart.... seems ugly. What about their insulin products? Diabetes is pretty much a "growth" story globally. Novo nordisk has been doing quite well on that.


    I guess could just stick with SNY BMY and PFE. BMY has been a dud recently, but SNY and PFE seem to be hanging in there well, especially SNY.
    12 Dec 2012, 09:09 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs